Dash Bio aims to accelerate drug development by replacing manual laboratory processes with automation and digital workflows. Dash Bio Raises $30 Million To Expand Automated Bioanalysis PlatformLife sciences venture firms invested to accelerate innovation across Dash Bio’s Automated Bioanalysis Platform for pharmaceutical companies. Dash Bio will expand laboratory capabilities, enhance proprietary software, and introduce additional bioanalysis testing services globally. Chief executive Dave Johnson, chief operating officer Ander Tallett, and chief scientific officer Ely Porter founded Dash Bio. The firm’s partners believe Dash Bio has developed a scalable platform capable of transforming laboratory services for modern drug development.